Epizyme (EPZM) Revised Celgene Agreement 'Net Positive', Mizuho Securities Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Extension of Celgene (CELG) Collaboration Highlights Partner Interest in Epizyme (EPZM) - Leerink
July 10, 2015 8:49 AM EDTLeerink affirmed Epizyme (Nasdaq: EPZM) at Outperform with a price target of $48 following new collaboration news issued Thursday.
Analyst Howard Liang, Ph.D, commented, We believe the extension of the research collaboration with Celgene (Nasdaq:... More
